專業從事
生命科學儀器技術服務13382235337
VIROGEN Corporation是研究和診斷市場抗原和抗體的供應商。我們位于世界科技中心大波士頓。該公司由哈佛大學和麻省理工學院的科學家于1995年創立
| 品牌 | 貨號 | 品名 | 規格 | 價格 |
| Virogen | 00211-V | HHV-4 recombinant p18 antigen Region: 1-119aa | 100ug/vial | 1800 |
| Virogen | 00212-V | HHV-4 recombinant mosaic EBNA1 antigen. Region: 1-90/408-498aa | 100ug/vial | 1800 |
| Virogen | 00213-V | HHV-4 recombinant EA antigen. Region: 306-390aa | 100ug/vial | 1800 |
| Virogen | 00167-V | HDV Ag recombinant antigen | 100ug/vial | 1800 |
| Virogen | 00214-V | Tick-born encephalitis virus gE recombinant antigen | 100ug/vial | 1800 |
| Virogen | 01005-V | Chlamydia trachomatis PDP3-D, Full length recombinant | 100ug/vial | 1800 |
| Virogen | 01011-V | Chlamydia trachomatis MOMP Recombinant antigen with out transmembrane domain. | 100ug/vial | 1800 |
| Virogen | 00206-V | Toxoplasma gondii MIC 3 recombinant antigen | 100ug/vial | 1800 |
| Virogen | 00207-V | Toxoplasma gondii P24 (GRA1) recombinant antigen | 100ug/vial | 1800 |
| Virogen | 00208-V | Toxoplasma gondii P29 (GRA7) recombinant antigen | 100ug/vial | 1800 |
| Virogen | 00209-V | Toxoplasma gondii P30 (SAG1) recombinant antigen | 100ug/vial | 1800 |
| Virogen | 00111-V | HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa | 100ug/vial | 1800 |
| Virogen | 00112-V | HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa | 100ug/vial | 1800 |
| Virogen | 00113-V | HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa | 100ug/vial | 1800 |
| Virogen | 00114-V | HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa | 100ug/vial | 1800 |
| Virogen | 00168-V | HIV-1 p17/24/gp120-gp41 recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00169-V | HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. | 100ug/vial | 1800 |
| Virogen | 00170-V | HIV-1 gp41 recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00171-V | HIV-1 gp41 Long recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00172-V | HIV-1 p17-p24 recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00173-V | HIV-2 gp32 recombinant antigen. . | 100ug/vial | 1800 |
| Virogen | 00174-V | HIV-1 p24 recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00175-V | HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. | 100ug/vial | 1800 |
| Virogen | 00176-V | HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. | 100ug/vial | 1800 |
| Virogen | 00177-V | HIV 1 p24 core recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00178-V | HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. | 100ug/vial | 1800 |
| Virogen | 00179-V | HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. | 100ug/vial | 1800 |
| Virogen | 00110-V | HIV-1 tat recombinant antigen full length 15 kDa | 100ug/vial | 1800 |
| Virogen | 00180-V | HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. | 100ug/vial | 1800 |
| Virogen | 00198-V | HIV-1 reverse transcriptase recombinant antigen. | 100ug/vial | 1800 |
| Virogen | 00199-V | HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). | 100ug/vial | 1800 |
| Virogen | 00115-V | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa | 100 ug/vial | 1800 |
| Virogen | 00115-V-B | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. | 100 ug/vial | 1800 |
| Virogen | 00115-V-F | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. | 100 ug/vial | 1800 |
| Virogen | 00115-V-R | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. | 100 ug/vial | 1800 |
| Virogen | 00116-V | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. | 100 ug/vial | 1800 |
| Virogen | 00116-V-B | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. | 100 ug/vial | 1800 |
| Virogen | 00116-V-F | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. | 100 ug/vial | 1800 |
| Virogen | 00116-V-R | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. | 100 ug/vial | 1800 |
| Virogen | 00117-V | HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa | 100 ug/vial | 1800 |
| Virogen | 00150-V | HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a | 100 ug/vial | 1800 |
| Virogen | 00151-V | HCV core 24 antigen. | 100 ug/vial | 1800 |
| Virogen | 00152-V | HCV core recombinant antigen a.a.105-302 | 100 ug/vial | 1800 |
| Virogen | 00153-V | HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a | 100 ug/vial | 1800 |
| Virogen | 00154-V | HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 | 100 ug/vial | 1800 |
| Virogen | 00155-V | HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. | 100 ug/vial | 1800 |
| Virogen | 00156-V | HCV NS4 1916-1947aa recombinant antigen. | 100 ug/vial | 1800 |
| Virogen | 00157-V | HCV NS5 2061-2302aa recombinant antigen. | 100 ug/vial | 1800 |
| Virogen | 00158-V | HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. | 100 ug/vial | 1800 |
| Virogen | 00120-V | HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa | 100 ug/vial | 1800 |
| Virogen | 00121-V | HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa | 100 ug/vial | 1800 |
| Virogen | 00122-V | HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant | 100 ug/vial | 1800 |
| Virogen | 00123-V | HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity | 100 ug/vial | 1800 |
| Virogen | 00124-V | HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant | 100 ug/vial | 1800 |
| Virogen | 00131-V | HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. | 100 ug/vial | 1800 |
| Virogen | 00132-V | HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. | 100 ug/vial | 1800 |
| Virogen | 00133-V | HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. | 100 ug/vial | 1800 |
| Virogen | 00141-V | T. Pallidum recombinant antigen p15 (full length) | 100 ug/vial | 1800 |
| Virogen | 00142-V | T. Pallidum recombinant antigen p17 (full length) | 100 ug/vial | 1800 |
| Virogen | 00143-V | T. Pallidum recombinant antigen p45 (full length) | 100 ug/vial | 1800 |
| Virogen | 00144-V | T. Pallidum recombinant antigen TmpA (full length) | 100 ug/vial | 1800 |
| Virogen | 00185-V | CMV Pp65 (UL83) recombinant antigen , full length | 100 ug/vial | 1800 |
| Virogen | 00188-V | CMV Pp65 (UL83) recombinant antigen a.a. 297-510 | 100 ug/vial | 1800 |
| Virogen | 00189-V | CMV Pp52 (UL44) recombinant antigen a.a. 271-428 | 100 ug/vial | 1800 |
| Virogen | 00187-V | CMV gB-AD1 (UL55) recombinant antigen a.a. 549-645 | 100 ug/vial | 1800 |
| Virogen | 00186-V | CMV Pp150 recombinant antigen a.a. 426-606 | 100 ug/vial | 1800 |
| Virogen | 00159-V | HAV VP1-P2A recombinant antigen a.a. 722-830. | 100 ug/vial | 1800 |
| Virogen | 00160-V | HAV VP4-VP2 recombinant antigen a.a. 55-164. | 100 ug/vial | 1800 |
| Virogen | 00161-V | HAV P2C-P3A recombinant antigen a.a. 1492-1606. | 100 ug/vial | 1800 |
| Virogen | 00162-V | HAV P3C recombinant antigen a.a. 1643-1743. | 100 ug/vial | 1800 |
| Virogen | 00163-V | HAV VP3 recombinant antigen a.a. 304-415. | 100 ug/vial | 1800 |
| Virogen | 00164-V | HAV VP1-P2A recombinant antigen a.a. 669-782. | 100 ug/vial | 1800 |
| Virogen | 00165-V | HAV HAV P2C recombinant antigen a.a. 1121-1234. | 100 ug/vial | 1800 |
| Virogen | 00166-V | HAV P2C-P3A recombinant antigen a.a. 1392-1521. | 100 ug/vial | 1800 |
| Virogen | 00181-V | HSV-1 gD recombinant antigen a.a. 266-394. | 100 ug/vial | 1800 |
| Virogen | 00182-V | HSV-2 gD recombinant antigen a.a. 266-394. | 100 ug/vial | 1800 |
| Virogen | 00183-V | HSV-2 gD recombinant antigen a.a. 525-578. | 100 ug/vial | 1800 |
| Virogen | 00184-V | HSV-1 gD recombinant antigen a.a. 84-175. | 100 ug/vial | 1800 |
| Virogen | 1131-V | HSV-2 gB recombinant antigen | 100 ug/vial | 1800 |
| Virogen | 1140-V | E. coli recombinant HSV II gG antigen. Immunodominant Region: a.a. 525-578 | 100 ug/vial | 1800 |
| Virogen | 00203-V | HLTV-I envelope recombinant antigen. C-terminus of gp-46 and most of p21. | 100 ug/vial | 1800 |
| Virogen | 00204-V | HLTV-I p24 core recombinant antigen. | 100 ug/vial | 1800 |
| Virogen | 00205-V | HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. | 100 ug/vial | 1800 |
| Virogen | 00700-V | HTLV-1 gp21 recombinant protein | 100 ug/vial | 1800 |
| Virogen | 00701-V | HTLV-1 gp46 recombinant protein | 100 ug/vial | 1800 |
| Virogen | 00215-V | Rubella virus E1 mosaic recombinant antigen a.a. 157-176/374-390/213-239. | 100 ug/vial | 1800 |
| Virogen | 00216-V | Rubella virus E2 recombinant antigen a.a. 31-105. | 100 ug/vial | 1800 |
| Virogen | 00217-V | Rubella virus capsid (C) recombinant antigen a.a. 1-123. | 100 ug/vial | 1800 |
| Virogen | 00191-V | SARS-Associated Coronavirus E recombinant antigen a.a. 1-76. | 100 ug/vial | 1800 |
| Virogen | 00192-V | SARS-Associated Coronavirus Nucleocapsid recombinant antigen N a.a. 1-49. | 100 ug/vial | 1800 |
| Virogen | 00193-V | SARS-Associated Coronavirus Nucleocapsid recombinant antigen C a.a. 340-390. | 100 ug/vial | 1800 |
| Virogen | 00194-V | SARS-Associated Coronavirus M recombinant antigen a.a. 182-216. | 100 ug/vial | 1800 |
| Virogen | 00195-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S(N) a.a. 12-53/90-115/171-203. | 100 ug/vial | 1800 |
| Virogen | 00196-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S(M) a.a. 408-470/540-573. | 100 ug/vial | 1800 |
| Virogen | 00197-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S© a.a. 1051-1076/1121-1154/1162-1190. | 100 ug/vial | 1800 |
| Virogen | 00200-V | VZV gE recombinant antigen a.a. 48-135. | 100 ug/vial | 1800 |
| Virogen | 00201-V | VZV ORF9 recombinant antigen a.a. 6-28/76-100. | 100 ug/vial | 1800 |
| Virogen | 00202-V | VZV ORF26 recombinant antigen a.a. 9-33/184-208. | 100 ug/vial | 1800 |
| Virogen | 00401-V | West Nile Virus Envelope recombinant antigen-Immunodominant region | 100 ug/vial | 1800 |
| Virogen | 00402-V | West Nile Virus Pre-M recombinant antigen-Immunodominant region | 100 ug/vial | 1800 |
| Virogen | 00403-V | West Nile Virus Envelope full length recombinant antigen 42 kDa region | 100 ug/vial | 1800 |
| Virogen | 00345-V | Zika Virus ENV -NS1 fusion antigen 54 kDa | 100 ug/vial | 1800 |
| Virogen | 00346-V | Zika Virus NS1 antigen 34 kDa | 100 ug/vial | 1800 |
| Virogen | 00347-V | H. pylori CogA antigen 34 kDa | 100 ug/vial | 1800 |
| Virogen | 00321-V | Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 | 100 ug/vial | 1800 |
| Virogen | 1170-V | Human Endogenous Retrovirus Envelope antigen 48 kDa | 100 ug/vial | 1800 |
| Virogen | 3001-V | Prostatic pacid hosphatase - full length (human) | 100 ug/vial | 1800 |
| Virogen | 3002-V | Ovine Prolactin | 100 ug/vial | 1800 |
| Virogen | 00900-V | Phospholipase A2 P00630 Bee Venom Recombinant Protein | 100 ug/vial | 1800 |
| Virogen | 00901-V | Soy Bean p34 Recombinant protein | 100 ug/vial | 1800 |
| Virogen | 900-V | Dermatophagoides farina Der F1 antigen (recombinant). Full length. Non enzymatically active. | 100 ug/vial | 1800 |
| Virogen | 901-V | Dermatophagoides pteronyssinus Der P1 antigen . Full length. Non enzymatically active. | 100 ug/vial | 1800 |
| Virogen | 012-A | anti-HIV-1 p24 IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 013-A | anti-HIV-1 p55/17 IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 014-A | anti-HIV-1 p17 IgG1 (monoclonal) Produced against a recombinant protein | 100 ug/vial | 1800 |
| Virogen | 0114-A | anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 015-A | anti-HIV-1 gp41 IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 016-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 017-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 018-A | anti-HCV NS4 IgG2a (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 020-A | anti-HSV (I) gD IgG1 (monoclonal) Produced against a HSV (I) viral concentrate | 100 ug/vial | 1800 |
| Virogen | 021-A | anti-HSV (II) gB IgG1 (monoclonal) Produced against a HSV (II) infected cells. | 100 ug/vial | 1800 |
| Virogen | 022-A | anti-HCMV IE pp72 IgG2a (monoclonal) Produced against a HCMV IE concentrate. | 100 ug/vial | 1800 |
| Virogen | 023-A | anti-HCMV IE pp65 IgG1 (monoclonal) Produced against a HCMV infected cells. | 100 ug/vial | 1800 |
| Virogen | 024-A | anti-HCMV gB IgG1 (monoclonal) Produced against a HCMV infected cells. | 100 ug/vial | 1800 |
| Virogen | 025-A | anti-Adenovirus E11 IgG2a (monoclonal) Produced against purified Ad1 virus | 100 ug/vial | 1800 |
| Virogen | 026-A | anti-Adenovirus C11 IgG2a (monoclonal) Produced against purified Ad7 virus | 100 ug/vial | 1800 |
| Virogen | 027-A | anti-Rotavirus p42 IgG2a (monoclonal) Produced against purified bovine rotavirus virus. | 100 ug/vial | 1800 |
| Virogen | 028-A | anti-TGE IgG1 (monoclonal) Produced against purified TGE virus 1E11. | 100 ug/vial | 1800 |
| Virogen | 030-A | anti-HBcAg core IgM (monoclonal) Produced against recombinant HBcAg core antigen. | 100 ug/vial | 1800 |
| Virogen | 031-A | anti-HBsAg pre-surface IgG1 (monoclonal) Produced against HBsAg purified from human sera pool. | 100 ug/vial | 1800 |
| Virogen | 032-A | anti-HBsAg surface antigen IgG1 (monoclonal) Produced against HBsAg purified from human sera pool. | 100 ug/vial | 1800 |
| Virogen | 033-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 70 – 80 a.a. | 100 ug/vial | 1800 |
| Virogen | 034-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope: 135-140 a.a. | 100 ug/vial | 1800 |
| Virogen | 035-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope:141-154 a.a. | 100 ug/vial | 1800 |
| Virogen | 036-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 1-10 a.a. | 100 ug/vial | 1800 |
| Virogen | 037-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope: 138- 145 a.a. | 100 ug/vial | 1800 |
| Virogen | 038-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 130-140 a.a. | 100 ug/vial | 1800 |
| Virogen | 0116-A | anti-HCV core IgG1 (monoclonal) Produced against a recombinant, HCV core 00115-V, protein. | 100 ug/vial | 1800 |
| Virogen | 0117-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant, HCV core 00115-V, protein. | 100 ug/vial | 1800 |
| Virogen | 216-A | anti-HCV core IgG1 (monoclonal)Produced against recombinant antigen | 100 ug/vial | 1800 |
| Virogen | 245-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen epitope a.a. 1748 to 1754 | 100 ug/vial | 1800 |
| Virogen | 246-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen | 100 ug/vial | 1800 |
| Virogen | 247-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen epitope a.a 1713 to 1717 | 100 ug/vial | 1800 |
| Virogen | 266-A | anti-HCV NS5b rabbit (polycnonal)Produced against a recombinant protein | 100 ug/vial | 1800 |
| Virogen | 199-A | anti-HCV NS5a rabbit (polycnonal) Produced against a recombinant protein | 100 ug/vial | 1800 |
| Virogen | 276-A | anti-Rotavirus p42 IgG2a (monoclonal) Produced against purified bovine rotavirus virus. | 100 ug/vial | 1800 |
| Virogen | 010-A | anti-Rabies G antigen monoclonal antibody. Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 111-A | anti-Dengue NS1 Type 2 IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 101-A | anti-Glutathione monoclonal antibody IgG1 | 100 ug/vial | 1800 |
| Virogen | 102-A | anti-Cysteine monoclonal antibody IgG1 | 100 ug/vial | 1800 |
| Virogen | 041-A | anti-Thyroxine monoclonal antibody IgG2a | 100 ug/vial | 1800 |
| Virogen | 011-A | anti-GSK3 Beta IgG2a (monoclonal). Produced against a recombinant Xenopus laevis protein. | 100 ug/vial | 1800 |
| Virogen | 019-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 029-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 039-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 100 ug/vial | 1800 |
| Virogen | 049-A | anti-FAS IgM (monoclonal) | 100 ug/vial | 1800 |
| Virogen | 059-A | anti-SLAM anti-CDw150 IgG2a (monoclonal) Produced against an activated B cell line. | 100 ug/vial | 1800 |
| Virogen | 069-A | anti-CD37 IgG2b (monoclonal) Produced against a B cell line. | 100 ug/vial | 1800 |
| Virogen | 079-A | anti-Nuclear Antigen (Proliferating Cells) IgM (monoclonal) Produced against a proliferating Harvey cell line. | 100 ug/vial | 1800 |
| Virogen | 066-A | anti-p53, clone BP53-12 | 100 ug/vial | 1800 |
| Virogen | 060-A | anti-CD3 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 061-A | anti-CD4 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 062-A | anti-CD8 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 063-A | anti-CD16 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 064-A | anti-CD20 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 065-A | anti-CD22 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 067-A | anti-CD45 RA IgG2 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 068-A | anti-CD54 IgG2b-k monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 071-A | anti-CD19 IgG1 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 089-A | anti-CD66e IgG1 monoclonal antibody | 100 ug/vial | 1800 |
| Virogen | 501-A | anti-CD3 T-cell | 100 ug/vial | 1800 |
| Virogen | 502-A | anti-CD4 T helper cells | 100 ug/vial | 1800 |
| Virogen | 503-A | anti-CD5 All T-cells | 100 ug/vial | 1800 |
| Virogen | 504-A | anti-CD7 All T-cells | 100 ug/vial | 1800 |
| Virogen | 505-A | anti-CD8 T cytotoxic/supressor cells | 100 ug/vial | 1800 |
| Virogen | 506-A | anti-CD10 Lymphoblasts | 100 ug/vial | 1800 |
| Virogen | 507-A | anti-CD16 NK-cells, monocytes, granulocytes | 100 ug/vial | 1800 |
| Virogen | 508-A | anti-CD18 Leucocytes | 100 ug/vial | 1800 |
| Virogen | 509-A | anti-CD20 B-lymphocytes | 100 ug/vial | 1800 |
| Virogen | 510-A | anti-CD22 B-lymphocytes | 100 ug/vial | 1800 |
| Virogen | 511-A | anti-CD25 IL-2 receptor expressed on activated T and B cells | 100 ug/vial | 1800 |
| Virogen | 512-A | anti-CD26 Activated T, B lymphocytes and macrophages | 100 ug/vial | 1800 |
| Virogen | 513-A | anti-CD34 Hematopoietic precursor cells | 100 ug/vial | 1800 |
| Virogen | 514-A | anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells | 100 ug/vial | 1800 |
| Virogen | 515-A | anti-CD45 Leukocytes | 100 ug/vial | 1800 |
| Virogen | 516-A | anti-CD45 RA B-cells, T-cells, NK-cells | 100 ug/vial | 1800 |
| Virogen | 517-A | anti-ICAM-3, Leukocytes | 100 ug/vial | 1800 |
| Virogen | 518-A | anti-Transferrin receptor on activated T-B-, cells | 100 ug/vial | 1800 |
| Virogen | 519-A | anti-FAS antigen | 100 ug/vial | 1800 |
| Virogen | 520-A | anti-HLA-DR | 100 ug/vial | 1800 |
| Virogen | 521-A | anti-HLA-ABC on all Leukocytes | 100 ug/vial | 1800 |
| Virogen | 522-A | anti-IgM Heavy chain expressed on B cells | 100 ug/vial | 1800 |
| Virogen | 523-A | anti-Cortical thymocytes | 100 ug/vial | 1800 |
| Virogen | 131-A | anti-RhoD human antigen IgG1 | 100ug/vial | 1800 |
| Virogen | 132-A | anti-A1, A2 human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 133-A | anti-A1, A2, A3 human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 134-A | anti-B human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 135-A | anti-AB human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 136-A | anti-Rh(o)D human antigen IgM | 100 ug/vial | 1800 |
| Virogen | 137-A | anti-Rh(o)D and Rh(o)Dii human Rhesus system antigen IgG1 | 100 ug/vial | 1800 |
| Virogen | 138-A | anti-RhoC human Rhesus system antigen IgM | 100 ug/vial | 1800 |
| Virogen | 139-A | anti-A1, A2 human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 140-A | anti-B human blood group antigen IgM | 100 ug/vial | 1800 |
| Virogen | 141-A | anti-H n/ab human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 142-A | anti-H ab human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 143-A | anti-H inh human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 144-A | anti-M human blood antigen IgM | 100 ug/vial | 1800 |
| Virogen | 145-A | anti-N human blood antigen Ig2b | 100 ug/vial | 1800 |
| Virogen | 146-A | Antiglobulin (COOMBS) Rabbit polyclonal | 100 ug/vial | 1800 |
| Virogen | 00211-V | HHV-4 recombinant p18 antigen Region: 1-119aa | 1 mg | 10200 |
| Virogen | 00212-V | HHV-4 recombinant mosaic EBNA1 antigen. Region: 1-90/408-498aa | 1 mg | 10200 |
| Virogen | 00213-V | HHV-4 recombinant EA antigen. Region: 306-390aa | 1 mg | 10200 |
| Virogen | 00167-V | HDV Ag recombinant antigen | 1 mg | 10200 |
| Virogen | 00214-V | Tick-born encephalitis virus gE recombinant antigen | 1 mg | 10200 |
| Virogen | 01005-V | Chlamydia trachomatis PDP3-D, Full length recombinant | 1 mg | 10200 |
| Virogen | 01011-V | Chlamydia trachomatis MOMP Recombinant antigen with out transmembrane domain. | 1 mg | 10200 |
| Virogen | 00206-V | Toxoplasma gondii MIC 3 recombinant antigen | 1 mg | 10200 |
| Virogen | 00207-V | Toxoplasma gondii P24 (GRA1) recombinant antigen | 1 mg | 10200 |
| Virogen | 00208-V | Toxoplasma gondii P29 (GRA7) recombinant antigen | 1 mg | 10200 |
| Virogen | 00209-V | Toxoplasma gondii P30 (SAG1) recombinant antigen | 1 mg | 10200 |
| Virogen | 00111-V | HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa | 1 mg | 10200 |
| Virogen | 00112-V | HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa | 1 mg | 10200 |
| Virogen | 00113-V | HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa | 1 mg | 10200 |
| Virogen | 00114-V | HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa | 1 mg | 10200 |
| Virogen | 00168-V | HIV-1 p17/24/gp120-gp41 recombinant antigen. | 1 mg | 10200 |
| Virogen | 00169-V | HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. | 1 mg | 10200 |
| Virogen | 00170-V | HIV-1 gp41 recombinant antigen. | 1 mg | 10200 |
| Virogen | 00171-V | HIV-1 gp41 Long recombinant antigen. | 1 mg | 10200 |
| Virogen | 00172-V | HIV-1 p17-p24 recombinant antigen. | 1 mg | 10200 |
| Virogen | 00173-V | HIV-2 gp32 recombinant antigen. . | 1 mg | 10200 |
| Virogen | 00174-V | HIV-1 p24 recombinant antigen. | 1 mg | 10200 |
| Virogen | 00175-V | HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. | 1 mg | 10200 |
| Virogen | 00176-V | HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. | 1 mg | 10200 |
| Virogen | 00177-V | HIV 1 p24 core recombinant antigen. | 1 mg | 10200 |
| Virogen | 00178-V | HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. | 1 mg | 10200 |
| Virogen | 00179-V | HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. | 1 mg | 10200 |
| Virogen | 00110-V | HIV-1 tat recombinant antigen full length 15 kDa | 1 mg | 10200 |
| Virogen | 00180-V | HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. | 1 mg | 10200 |
| Virogen | 00198-V | HIV-1 reverse transcriptase recombinant antigen. | 1 mg | 10200 |
| Virogen | 00199-V | HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). | 1 mg | 10200 |
| Virogen | 00115-V | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa | 1 mg | 10200 |
| Virogen | 00115-V-B | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. | 1 mg | 10200 |
| Virogen | 00115-V-F | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. | 1 mg | 10200 |
| Virogen | 00115-V-R | HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. | 1 mg | 10200 |
| Virogen | 00116-V | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. | 1 mg | 10200 |
| Virogen | 00116-V-B | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. | 1 mg | 10200 |
| Virogen | 00116-V-F | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. | 1 mg | 10200 |
| Virogen | 00116-V-R | HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. | 1 mg | 10200 |
| Virogen | 00117-V | HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa | 1 mg | 10200 |
| Virogen | 00150-V | HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a | 1 mg | 10200 |
| Virogen | 00151-V | HCV core 24 antigen. | 1 mg | 10200 |
| Virogen | 00152-V | HCV core recombinant antigen a.a.105-302 | 1 mg | 10200 |
| Virogen | 00153-V | HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a | 1 mg | 10200 |
| Virogen | 00154-V | HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 | 1 mg | 10200 |
| Virogen | 00155-V | HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. | 1 mg | 10200 |
| Virogen | 00156-V | HCV NS4 1916-1947aa recombinant antigen. | 1 mg | 10200 |
| Virogen | 00157-V | HCV NS5 2061-2302aa recombinant antigen. | 1 mg | 10200 |
| Virogen | 00158-V | HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. | 1 mg | 10200 |
| Virogen | 00120-V | HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa | 1 mg | 10200 |
| Virogen | 00121-V | HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa | 1 mg | 10200 |
| Virogen | 00122-V | HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant | 1 mg | 10200 |
| Virogen | 00123-V | HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity | 1 mg | 10200 |
| Virogen | 00124-V | HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant | 1 mg | 10200 |
| Virogen | 00131-V | HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. | 1 mg | 10200 |
| Virogen | 00132-V | HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. | 1 mg | 10200 |
| Virogen | 00133-V | HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. | 1 mg | 10200 |
| Virogen | 00141-V | T. Pallidum recombinant antigen p15 (full length) | 1 mg | 10200 |
| Virogen | 00142-V | T. Pallidum recombinant antigen p17 (full length) | 1 mg | 10200 |
| Virogen | 00143-V | T. Pallidum recombinant antigen p45 (full length) | 1 mg | 10200 |
| Virogen | 00144-V | T. Pallidum recombinant antigen TmpA (full length) | 1 mg | 10200 |
| Virogen | 00185-V | CMV Pp65 (UL83) recombinant antigen , full length | 1 mg | 10200 |
| Virogen | 00188-V | CMV Pp65 (UL83) recombinant antigen a.a. 297-510 | 1 mg | 10200 |
| Virogen | 00189-V | CMV Pp52 (UL44) recombinant antigen a.a. 271-428 | 1 mg | 10200 |
| Virogen | 00187-V | CMV gB-AD1 (UL55) recombinant antigen a.a. 549-645 | 1 mg | 10200 |
| Virogen | 00186-V | CMV Pp150 recombinant antigen a.a. 426-606 | 1 mg | 10200 |
| Virogen | 00159-V | HAV VP1-P2A recombinant antigen a.a. 722-830. | 1 mg | 10200 |
| Virogen | 00160-V | HAV VP4-VP2 recombinant antigen a.a. 55-164. | 1 mg | 10200 |
| Virogen | 00161-V | HAV P2C-P3A recombinant antigen a.a. 1492-1606. | 1 mg | 10200 |
| Virogen | 00162-V | HAV P3C recombinant antigen a.a. 1643-1743. | 1 mg | 10200 |
| Virogen | 00163-V | HAV VP3 recombinant antigen a.a. 304-415. | 1 mg | 10200 |
| Virogen | 00164-V | HAV VP1-P2A recombinant antigen a.a. 669-782. | 1 mg | 10200 |
| Virogen | 00165-V | HAV HAV P2C recombinant antigen a.a. 1121-1234. | 1 mg | 10200 |
| Virogen | 00166-V | HAV P2C-P3A recombinant antigen a.a. 1392-1521. | 1 mg | 10200 |
| Virogen | 00181-V | HSV-1 gD recombinant antigen a.a. 266-394. | 1 mg | 10200 |
| Virogen | 00182-V | HSV-2 gD recombinant antigen a.a. 266-394. | 1 mg | 10200 |
| Virogen | 00183-V | HSV-2 gD recombinant antigen a.a. 525-578. | 1 mg | 10200 |
| Virogen | 00184-V | HSV-1 gD recombinant antigen a.a. 84-175. | 1 mg | 10200 |
| Virogen | 1131-V | HSV-2 gB recombinant antigen | 1 mg | 10200 |
| Virogen | 1140-V | E. coli recombinant HSV II gG antigen. Immunodominant Region: a.a. 525-578 | 1 mg | 10200 |
| Virogen | 00203-V | HLTV-I envelope recombinant antigen. C-terminus of gp-46 and most of p21. | 1 mg | 10200 |
| Virogen | 00204-V | HLTV-I p24 core recombinant antigen. | 1 mg | 10200 |
| Virogen | 00205-V | HTLV-1 virus mosaic recombinant antigen a.a. 374-400/190-207. | 1 mg | 10200 |
| Virogen | 00700-V | HTLV-1 gp21 recombinant protein | 1 mg | 10200 |
| Virogen | 00701-V | HTLV-1 gp46 recombinant protein | 1 mg | 10200 |
| Virogen | 00215-V | Rubella virus E1 mosaic recombinant antigen a.a. 157-176/374-390/213-239. | 1 mg | 10200 |
| Virogen | 00216-V | Rubella virus E2 recombinant antigen a.a. 31-105. | 1 mg | 10200 |
| Virogen | 00217-V | Rubella virus capsid (C) recombinant antigen a.a. 1-123. | 1 mg | 10200 |
| Virogen | 00191-V | SARS-Associated Coronavirus E recombinant antigen a.a. 1-76. | 1 mg | 10200 |
| Virogen | 00192-V | SARS-Associated Coronavirus Nucleocapsid recombinant antigen N a.a. 1-49. | 1 mg | 10200 |
| Virogen | 00193-V | SARS-Associated Coronavirus Nucleocapsid recombinant antigen C a.a. 340-390. | 1 mg | 10200 |
| Virogen | 00194-V | SARS-Associated Coronavirus M recombinant antigen a.a. 182-216. | 1 mg | 10200 |
| Virogen | 00195-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S(N) a.a. 12-53/90-115/171-203. | 1 mg | 10200 |
| Virogen | 00196-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S(M) a.a. 408-470/540-573. | 1 mg | 10200 |
| Virogen | 00197-V | SARS-Associated Coronavirus Spike mosaic recombinant antigen S© a.a. 1051-1076/1121-1154/1162-1190. | 1 mg | 10200 |
| Virogen | 00200-V | VZV gE recombinant antigen a.a. 48-135. | 1 mg | 10200 |
| Virogen | 00201-V | VZV ORF9 recombinant antigen a.a. 6-28/76-100. | 1 mg | 10200 |
| Virogen | 00202-V | VZV ORF26 recombinant antigen a.a. 9-33/184-208. | 1 mg | 10200 |
| Virogen | 00401-V | West Nile Virus Envelope recombinant antigen-Immunodominant region | 1 mg | 10200 |
| Virogen | 00402-V | West Nile Virus Pre-M recombinant antigen-Immunodominant region | 1 mg | 10200 |
| Virogen | 00403-V | West Nile Virus Envelope full length recombinant antigen 42 kDa region | 1 mg | 10200 |
| Virogen | 00345-V | Zika Virus ENV -NS1 fusion antigen 54 kDa | 1 mg | 10200 |
| Virogen | 00346-V | Zika Virus NS1 antigen 34 kDa | 1 mg | 10200 |
| Virogen | 00347-V | H. pylori CogA antigen 34 kDa | 1 mg | 10200 |
| Virogen | 00321-V | Giardia Trophozoite Recombinant antigen antigen 34 kDa a.a. 21-280 | 1 mg | 10200 |
| Virogen | 1170-V | Human Endogenous Retrovirus Envelope antigen 48 kDa | 1 mg | 10200 |
| Virogen | 3001-V | Prostatic pacid hosphatase - full length (human) | 1 mg | 10200 |
| Virogen | 3002-V | Ovine Prolactin | 1 mg | 10200 |
| Virogen | 00900-V | Phospholipase A2 P00630 Bee Venom Recombinant Protein | 1 mg | 10200 |
| Virogen | 00901-V | Soy Bean p34 Recombinant protein | 1 mg | 10200 |
| Virogen | 900-V | Dermatophagoides farina Der F1 antigen (recombinant). Full length. Non enzymatically active. | 1 mg | 10200 |
| Virogen | 901-V | Dermatophagoides pteronyssinus Der P1 antigen . Full length. Non enzymatically active. | 1 mg | 10200 |
| Virogen | 012-A | anti-HIV-1 p24 IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 013-A | anti-HIV-1 p55/17 IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 014-A | anti-HIV-1 p17 IgG1 (monoclonal) Produced against a recombinant protein | 1 mg | 10200 |
| Virogen | 0114-A | anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 015-A | anti-HIV-1 gp41 IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 016-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 017-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 018-A | anti-HCV NS4 IgG2a (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 020-A | anti-HSV (I) gD IgG1 (monoclonal) Produced against a HSV (I) viral concentrate | 1 mg | 10200 |
| Virogen | 021-A | anti-HSV (II) gB IgG1 (monoclonal) Produced against a HSV (II) infected cells. | 1 mg | 10200 |
| Virogen | 022-A | anti-HCMV IE pp72 IgG2a (monoclonal) Produced against a HCMV IE concentrate. | 1 mg | 10200 |
| Virogen | 023-A | anti-HCMV IE pp65 IgG1 (monoclonal) Produced against a HCMV infected cells. | 1 mg | 10200 |
| Virogen | 024-A | anti-HCMV gB IgG1 (monoclonal) Produced against a HCMV infected cells. | 1 mg | 10200 |
| Virogen | 025-A | anti-Adenovirus E11 IgG2a (monoclonal) Produced against purified Ad1 virus | 1 mg | 10200 |
| Virogen | 026-A | anti-Adenovirus C11 IgG2a (monoclonal) Produced against purified Ad7 virus | 1 mg | 10200 |
| Virogen | 027-A | anti-Rotavirus p42 IgG2a (monoclonal) Produced against purified bovine rotavirus virus. | 1 mg | 10200 |
| Virogen | 028-A | anti-TGE IgG1 (monoclonal) Produced against purified TGE virus 1E11. | 1 mg | 10200 |
| Virogen | 030-A | anti-HBcAg core IgM (monoclonal) Produced against recombinant HBcAg core antigen. | 1 mg | 10200 |
| Virogen | 031-A | anti-HBsAg pre-surface IgG1 (monoclonal) Produced against HBsAg purified from human sera pool. | 1 mg | 10200 |
| Virogen | 032-A | anti-HBsAg surface antigen IgG1 (monoclonal) Produced against HBsAg purified from human sera pool. | 1 mg | 10200 |
| Virogen | 033-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 70 – 80 a.a. | 1 mg | 10200 |
| Virogen | 034-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope: 135-140 a.a. | 1 mg | 10200 |
| Virogen | 035-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope:141-154 a.a. | 1 mg | 10200 |
| Virogen | 036-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 1-10 a.a. | 1 mg | 10200 |
| Virogen | 037-A | anti-HBcAg core IgG2b (monoclonal) Produced against recombinant HBcAg core antigen (ayw). Epitope: 138- 145 a.a. | 1 mg | 10200 |
| Virogen | 038-A | anti-HBcAg core IgG2a (monoclonal) Produced against recombinant HBcAg core antigen. Epitope: 130-140 a.a. | 1 mg | 10200 |
| Virogen | 0116-A | anti-HCV core IgG1 (monoclonal) Produced against a recombinant, HCV core 00115-V, protein. | 1 mg | 10200 |
| Virogen | 0117-A | anti-HCV core IgG2a (monoclonal) Produced against a recombinant, HCV core 00115-V, protein. | 1 mg | 10200 |
| Virogen | 216-A | anti-HCV core IgG1 (monoclonal)Produced against recombinant antigen | 1 mg | 10200 |
| Virogen | 245-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen epitope a.a. 1748 to 1754 | 1 mg | 10200 |
| Virogen | 246-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen | 1 mg | 10200 |
| Virogen | 247-A | anti-HCV NS4B IgG2b (monoclonal)Produced against recombinant antigen epitope a.a 1713 to 1717 | 1 mg | 10200 |
| Virogen | 266-A | anti-HCV NS5b rabbit (polycnonal)Produced against a recombinant protein | 1 mg | 10200 |
| Virogen | 199-A | anti-HCV NS5a rabbit (polycnonal) Produced against a recombinant protein | 1 mg | 10200 |
| Virogen | 276-A | anti-Rotavirus p42 IgG2a (monoclonal) Produced against purified bovine rotavirus virus. | 1 mg | 10200 |
| Virogen | 010-A | anti-Rabies G antigen monoclonal antibody. Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 111-A | anti-Dengue NS1 Type 2 IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 101-A | anti-Glutathione monoclonal antibody IgG1 | 1 mg | 10200 |
| Virogen | 102-A | anti-Cysteine monoclonal antibody IgG1 | 1 mg | 10200 |
| Virogen | 041-A | anti-Thyroxine monoclonal antibody IgG2a | 1 mg | 10200 |
| Virogen | 011-A | anti-GSK3 Beta IgG2a (monoclonal). Produced against a recombinant Xenopus laevis protein. | 1 mg | 10200 |
| Virogen | 019-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 029-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 039-A | anti-FAS IgG1 (monoclonal) Produced against a recombinant protein. | 1 mg | 10200 |
| Virogen | 049-A | anti-FAS IgM (monoclonal) | 1 mg | 10200 |
| Virogen | 059-A | anti-SLAM anti-CDw150 IgG2a (monoclonal) Produced against an activated B cell line. | 1 mg | 10200 |
| Virogen | 069-A | anti-CD37 IgG2b (monoclonal) Produced against a B cell line. | 1 mg | 10200 |
| Virogen | 079-A | anti-Nuclear Antigen (Proliferating Cells) IgM (monoclonal) Produced against a proliferating Harvey cell line. | 1 mg | 10200 |
| Virogen | 066-A | anti-p53, clone BP53-12 | 1 mg | 10200 |
| Virogen | 060-A | anti-CD3 monoclonal antibody | 1 mg | 10200 |
| Virogen | 061-A | anti-CD4 monoclonal antibody | 1 mg | 10200 |
| Virogen | 062-A | anti-CD8 monoclonal antibody | 1 mg | 10200 |
| Virogen | 063-A | anti-CD16 monoclonal antibody | 1 mg | 10200 |
| Virogen | 064-A | anti-CD20 monoclonal antibody | 1 mg | 10200 |
| Virogen | 065-A | anti-CD22 monoclonal antibody | 1 mg | 10200 |
| Virogen | 067-A | anti-CD45 RA IgG2 monoclonal antibody | 1 mg | 10200 |
| Virogen | 068-A | anti-CD54 IgG2b-k monoclonal antibody | 1 mg | 10200 |
| Virogen | 071-A | anti-CD19 IgG1 monoclonal antibody | 1 mg | 10200 |
| Virogen | 089-A | anti-CD66e IgG1 monoclonal antibody | 1 mg | 10200 |
| Virogen | 501-A | anti-CD3 T-cell | 1 mg | 10200 |
| Virogen | 502-A | anti-CD4 T helper cells | 1 mg | 10200 |
| Virogen | 503-A | anti-CD5 All T-cells | 1 mg | 10200 |
| Virogen | 504-A | anti-CD7 All T-cells | 1 mg | 10200 |
| Virogen | 505-A | anti-CD8 T cytotoxic/supressor cells | 1 mg | 10200 |
| Virogen | 506-A | anti-CD10 Lymphoblasts | 1 mg | 10200 |
| Virogen | 507-A | anti-CD16 NK-cells, monocytes, granulocytes | 1 mg | 10200 |
| Virogen | 508-A | anti-CD18 Leucocytes | 1 mg | 10200 |
| Virogen | 509-A | anti-CD20 B-lymphocytes | 1 mg | 10200 |
| Virogen | 510-A | anti-CD22 B-lymphocytes | 1 mg | 10200 |
| Virogen | 511-A | anti-CD25 IL-2 receptor expressed on activated T and B cells | 1 mg | 10200 |
| Virogen | 512-A | anti-CD26 Activated T, B lymphocytes and macrophages | 1 mg | 10200 |
| Virogen | 513-A | anti-CD34 Hematopoietic precursor cells | 1 mg | 10200 |
| Virogen | 514-A | anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells | 1 mg | 10200 |
| Virogen | 515-A | anti-CD45 Leukocytes | 1 mg | 10200 |
| Virogen | 516-A | anti-CD45 RA B-cells, T-cells, NK-cells | 1 mg | 10200 |
| Virogen | 517-A | anti-ICAM-3, Leukocytes | 1 mg | 10200 |
| Virogen | 518-A | anti-Transferrin receptor on activated T-B-, cells | 1 mg | 10200 |
| Virogen | 519-A | anti-FAS antigen | 1 mg | 10200 |
| Virogen | 520-A | anti-HLA-DR | 1 mg | 10200 |
| Virogen | 521-A | anti-HLA-ABC on all Leukocytes | 1 mg | 10200 |
| Virogen | 522-A | anti-IgM Heavy chain expressed on B cells | 1 mg | 10200 |
| Virogen | 523-A | anti-Cortical thymocytes | 1 mg | 10200 |
| Virogen | 131-A | anti-RhoD human antigen IgG1 | 1 mg | 10200 |
| Virogen | 132-A | anti-A1, A2 human blood antigen IgM | 1 mg | 10200 |
| Virogen | 133-A | anti-A1, A2, A3 human blood antigen IgM | 1 mg | 10200 |
| Virogen | 134-A | anti-B human blood antigen IgM | 1 mg | 10200 |
| Virogen | 135-A | anti-AB human blood antigen IgM | 1 mg | 10200 |
| Virogen | 136-A | anti-Rh(o)D human antigen IgM | 1 mg | 10200 |
| Virogen | 137-A | anti-Rh(o)D and Rh(o)Dii human Rhesus system antigen IgG1 | 1 mg | 10200 |
| Virogen | 138-A | anti-RhoC human Rhesus system antigen IgM | 1 mg | 10200 |
| Virogen | 139-A | anti-A1, A2 human blood antigen IgM | 1 mg | 10200 |
| Virogen | 140-A | anti-B human blood group antigen IgM | 1 mg | 10200 |
| Virogen | 141-A | anti-H n/ab human blood antigen IgM | 1 mg | 10200 |
| Virogen | 142-A | anti-H ab human blood antigen IgM | 1 mg | 10200 |
| Virogen | 143-A | anti-H inh human blood antigen IgM | 1 mg | 10200 |
| Virogen | 144-A | anti-M human blood antigen IgM | 1 mg | 10200 |
| Virogen | 145-A | anti-N human blood antigen Ig2b | 1 mg | 10200 |
| Virogen | 146-A | Antiglobulin (COOMBS) Rabbit polyclonal | 1 mg | 10200 |
無錫藥科美生物科技有限公司專業從事生命科學行業前沿技術服務與產品進出口服務，歡迎訂購咨詢全球各國各種進口產品。
歡迎來到
聯系人：賴秀麗
地址：無錫市惠山區惠山大道1699號惠山生命科技園C區5棟5315室
郵箱：46606436@qq.com
傳真：